BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Amid the brouhaha over Alnylam’s disappointing and perhaps confusing HELIOS-B data presentation last week, competitor BridgeBio is — at least publicly — attempting to stay above the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BeiGene plots to further build its manufacturing muscle outside of China

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 25, 2024

Moderna reports net loss of $4.7bn for full year 2023

Share this article Moderna reported a net income of $217m in Q4 2023, a decrease from $1.5bn in the same quarter of 2022. Credit: pcruciatti

February 23, 2024

Seaport emerges after $100m raise with ex-Karuna team at helm – Pharmaceutical Technology

Share this article Bristol-Myers Squibb acquired Karuna for $14bn in late 2023. Image credit: Shutterstock/Mr.Che. Seaport Therapeutics has entered the neuropsychiatry treatment space after emerging

April 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.